UroGen nabs $120M to support potential 2024 NDA filing, launch of bladder cancer chemo gel
UroGen Pharma’s hydrogel formulation of a decades-old cancer drug met the primary endpoints in two Phase III trials of a subset of bladder cancer, the biotech said Thursday morning.
The data intrigued investors enough to back a $120 million private placement that will help bankroll a potential NDA filing in the second half of next year, as well as a potential launch of the drug, CEO and president Liz Barrett told Endpoints News.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.